A new high-throughput strategy targeting MDM2 aims to overcome radiation resistance in uveal melanoma, a malignancy where treatment durability remains a core challenge. The work outlines a screening and intervention approach built for throughput—designed to identify workable MDM2-related combinations or mechanisms that can be progressed into subsequent testing. By focusing on a pathway often implicated in tumor stress responses and survival signaling, the effort seeks to directly address resistance that limits the benefit of radiation. The article frames the method as a platform advance that could speed exploration of MDM2-targeted countermeasures in an otherwise difficult ocular oncology setting.